Literature DB >> 10688802

Porphyrin and phthalocyanine antiscrapie compounds.

S A Priola1, A Raines, W S Caughey.   

Abstract

The transmissible spongiform encephalopathies (TSEs) are fatal, neurodegenerative diseases for which no effective treatments are available. The likelihood that a bovine form of TSE has crossed species barriers and infected humans underscores the urgent need to identify anti-TSE drugs. Certain cyclic tetrapyrroles (porphyrins and phthalocyanines) have recently been shown to inhibit the in vitro formation of PrP-res, a protease-resistant protein critical for TSE pathogenesis. We now report that treatment of TSE-infected animals with three such compounds increased survival time from 50 to 300%. The significant inhibition of TSE disease by structurally dissimilar tetrapyrroles identifies these compounds as anti-TSE drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688802     DOI: 10.1126/science.287.5457.1503

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  64 in total

1.  Inhibition of protease-resistant prion protein accumulation in vitro by curcumin.

Authors:  Byron Caughey; Lynne D Raymond; Gregory J Raymond; Laura Maxson; Jay Silveira; Gerald S Baron
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 2.  Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances.

Authors:  Maria Caramelli; Giuseppe Ru; Pierluigi Acutis; Gianluigi Forloni
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Inhibition of protease-resistant prion protein formation in a transformed deer cell line infected with chronic wasting disease.

Authors:  Gregory J Raymond; Emily A Olsen; Kil Sun Lee; Lynne D Raymond; P Kruger Bryant; Gerald S Baron; Winslow S Caughey; David A Kocisko; Linda E McHolland; Cynthia Favara; Jan P M Langeveld; Fred G van Zijderveld; Richard T Mayer; Michael W Miller; Elizabeth S Williams; Byron Caughey
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo.

Authors:  David A Kocisko; Byron Caughey
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products.

Authors:  David A Kocisko; Gerald S Baron; Richard Rubenstein; Jiancao Chen; Salomon Kuizon; Byron Caughey
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  De novo designed cyclic-peptide heme complexes.

Authors:  Michael M Rosenblatt; Jiangyun Wang; Kenneth S Suslick
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

7.  meso-Tetra(pentafluorophenyl)porphyrin as an efficient platform for combinatorial synthesis and the selection of new photodynamic therapeutics using a cancer cell line.

Authors:  Diana Samaroo; Mikki Vinodu; Xin Chen; Charles Michael Drain
Journal:  J Comb Chem       Date:  2007-09-15

8.  Effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prions.

Authors:  Chang-Hyun Song; Osamu Honmou; Natsuo Ohsawa; Kiminori Nakamura; Hirofumi Hamada; Hidefumi Furuoka; Rie Hasebe; Motohiro Horiuchi
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Progress and problems in the biology, diagnostics, and therapeutics of prion diseases.

Authors:  Adriano Aguzzi; Mathias Heikenwalder; Gino Miele
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

10.  Acridine derivatives inhibit lysozyme aggregation.

Authors:  Zuzana Gazova; Andrea Bellova; Zuzana Daxnerova; Jan Imrich; Pavol Kristian; Jana Tomascikova; Jaroslava Bagelova; Diana Fedunova; Marian Antalik
Journal:  Eur Biophys J       Date:  2008-04-03       Impact factor: 1.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.